World Health Organisation (WHO) delineated cancer as one of the foremost reasons for mortality with 10 million deaths in the year 2020. Early diagnosis and effective drug delivery are of utmost importance in cancer management. The entrapment of both bio-imaging dyes and drugs will open novel avenues in the area of tumor theranostics. Elevated levels of reactive oxygen species (ROS) and glutathione (GSH) are the characteristic features of the tumor microenvironment (TME). Researchers have taken advantage of these specific TME features in recent years to develop micelle-based theranostic nanosystems. This review focuses on the advantages of redox-sensitive micelles (RSMs) and supramolecular self-assemblies for tumor theranostics. Key chemical linkers employed for the tumor-specific release of the cargo have been discussed. In vitro characterisation techniques used for the characterization of RSMs have been deliberated. Potential bottlenecks that may present themselves in the bench-to-bedside translation of this technology and the regulatory considerations have been deliberated.

世界卫生组织 (WHO) 将癌症描述为 2020 年有 1000 万人死亡的首要原因之一。早期诊断和有效的药物输送在癌症管理中至关重要。生物成像染料和药物的捕获将为肿瘤治疗学领域开辟新的途径。活性氧 (ROS) 和谷胱甘肽 (GSH) 水平升高是肿瘤微环境 (TME) 的特征。近年来，研究人员利用这些特定的 TME 特征开发了基于胶束的治疗诊断纳米系统。本综述重点介绍了氧化还原敏感胶束 (RSM) 和超分子自组装在肿瘤治疗学中的优势。已经讨论了用于货物的肿瘤特异性释放的关键化学接头。已经讨论了用于表征 RSM 的体外表征技术。已经考虑了在该技术的实验室到床边翻译中可能出现的潜在瓶颈以及监管考虑。